An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Summary

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.

Timeline

Start

2025-12-12

Primary completion

2028-12-15

Completion

2029-04-15

Drugs

Indications